Biotech Holdings Ltd. (OTCBB: BIOHF, TSX-V: BIO) is a pharmaceutical production and distribution company based in Vancouver, Canada. The company has developed an important new anti-diabetic medication, which has been trademarked as “Sucanon” and “Diab II”. Biotech is now focused on the distribution and marketing of this medication. The Company also looks forward to the development of combination therapies using this new proprietary medication in combination with other well-established treatments for Type II Diabetes, which is one of the world’s most widespread and rapidly growing diseases.
Sucanon has been proven effective in clinical trials. The drug has been approved by regulatory authorities in Mexico and is widely sold in that country including by Costco Mexico and Wal-Mart Mexico. Sucanon is also available by internet to Type II Diabetics in North America and elsewhere who are buying for personal use.
Expanded Distribution
Biotech Holdings reported at the end of May that the Company has signed an agreement for distribution of Sucanon in four markets in Latin America. The four additional markets – Colombia, Peru, Ecuador and Costa Rica – will be served by a private company based in Bogota, Colombia. The private company, unrelated to Biotech Holdings, focuses on sales of antibiotic products and has subsidiary operations in several Latin American countries.
Biotech will carry out tableting and blister-packing of Sucanon tablets through a company which it sub-contracts in Mexico, and sell the blisterpacked product to the Colombian company. The Colombian company will add country-specific external packaging for each of the different markets for which it is licensed and distribute to those markets.
The Colombian company will also be responsible for arranging and paying for all marketing and advertising expenditures in those markets. In order to speed revenue growth in these new markets, Biotech Holdings will transfer to the Colombian company the advertising and marketing expertise that Biotech has gained while marketing Sucanon in Mexico. Colombia, with approximately 44 million people, is the largest of these markets. The four markets have a combined population of approximately 90 million and are typified by high rates of Type II Diabetes, affecting approximately 15% of the adult population.
Product Information – Sucanon™
Sucanon™ acts to increase the body’s ability to utilize its insulin, resulting in improved metabolism and an enhanced sense of well-being for the patient. This increased insulin sensitivity results in decreased blood sugar levels in those suffering from Type II Diabetes. Sucanon™ is one of only three drugs approved anywhere in the world, belonging to a new category of drugs called “insulin sensitizers”.
Clinical studies involving three hospitals and 1,500 patients were completed in China. A high satisfaction rate was indicated by a post-clinical trial poll and by follow-up data on 7,600 patients, reported in 2001. In preparation for regulatory applications to be made throughout Latin America, a supplementary and confirming clinical trial was carried out in Brazil.
The drug has received regulatory approval in Mexico and Peru. Sales in Mexico began in early 2005 under the tradename “Sucanon”. Sales in Peru are projected to begin in 2006, under the trade name “Glucanin”. Production of key ingredients of the drug is carred out at Biotech’s plant in suburban Vancouver; talbeting and packaging is done in Mexico City for the Mexican market and is projected to be done in Lima for the Peru market.
Mexico is the eighth largest pharmaceutical market and one of the largest diabetic markets in the world.
Type II Diabetes
Type I or “Juvenile Onset” Diabetes is inborn and leads to the loss of most or all insulin production by the pancreas in the person’s childhood.
Type II diabetes, by contrast, typically affects people in adulthood and develops at least partly due to lifestyle factors. Type II or “Adult Onset” Diabetes is the most common form of diabetes, accounting for approximately 90% of all diabetic cases.
All diabetic conditions are characterized by chronically high blood sugar levels, leading over time to extensive damage to the vascular system including the heart and kidneys and to loss of sensitivity and functions in the extremities. Over time, high blood sugar can lead to heart problems, kidney problems, stroke, blindess, impotence , loss of circulation in the fingers and toes, development of gangrene and amputations.
Sucanon is effective for reducing the symptoms of Type II Diabetes.
View the StockGuru Profile for Biotech Holdings:
http://www.stockguru.com/profiles/biohf/
We Invite you to Visit the All New StockGuru Blog!
Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.
Click HERE to visit the Blog, or go to:
http://stockguru.com/blog/
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure:Pentony Enterprises LLC has been compensated $30,000 by a non-controlling thrid party for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.